製品番号: HY-N0026

2'-Acetylacteoside

(別名: 2'-AA; 2'-アセチルアクテオシド)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC₅₀ = 17.71 μM, K_i = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.73%
CAS 番号: 94492-24-7
分子式: C₃₁H₃₈O₁₆
分子量:666.62

保管条件:

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

2'-Acetylacteoside 構造式

CAS 番号: 94492-24-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (1)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[2]

MAO-B

NF-κB

IKKβ

Monoamine Oxidase アイソフォーム固有の製品をすべて表示 :

MAO-A
MAO-B

TNF Receptor アイソフォーム固有の製品をすべて表示 :

NF-κB アイソフォーム固有の製品をすべて表示 :

IKK アイソフォーム固有の製品をすべて表示 :

体外実験

2'-Acetylacteoside (10^-7-10^-5 mol/L; 0.5 h, 24 h, 6 days) inhibits RANKL-induced osteoclast differentiation of RAW264.7 cells and down-regulates the expression of key proteins in the RANKL/RANK/TRAF6-mediated NF-κB/NFATc1 pathway^[1].
2'-Acetylacteoside binds to Akt3 protein in cultured adult SVZ-derived NSCs, protecting it from protease degradation^[2].
2'-Acetylacteoside (5-40 μM; 24 h) promotes proliferation of OGD/R-treated adult SVZ-derived NSCs^[2].
2'-Acetylacteoside (10 μM; 24 h) enhances the proliferation of OGD/R-treated adult SVZ-derived NSCs in vitro, as shown by a significant increase in EdU-positive cells^[2].
2'-Acetylacteoside (10 μM) promotes differentiation of OGD/R-treated adult SVZ-derived NSCs into immature neurons (DCX-positive) in vitro, without affecting gliogenesis^[2].
2'-Acetylacteoside (10 μM) promotes proliferation and neurogenesis of OGD/R-treated adult SVZ-derived NSCs in vitro via activation of the PI3K/Akt pathway, as shown by increased p-Akt, p-CREB, DCX, and NeuN expression^[2].
2'-Acetylacteoside alters gene expression in OGD/R-treated adult SVZ-derived NSCs in vitro, with significant enrichment of differentially expressed genes in the PI3K/Akt signaling pathway, and up-regulates neurogenesis-related genes including VEGFα, Errb4, Col1a1, and Igfbp5^[2].
2'-Acetylacteoside potently inhibited purified MAO-B enzyme in vitro with an IC₅₀ of 17.71 μM and acted as a reversible mixed inhibitor with high affinity for free MAO-B (Ki = 13.81 μM)^[3].
2'-Acetylacteoside (25-100 μM) scavenges superoxide radicals in a concentration-dependent manner in a cell-free in vitro system^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

cultured adult subventricular zone (SVZ)-derived neural stem cells (NSCs) under oxygen-glucose deprivation/reoxygenation (OGD/R) conditions
Concentration:

5, 10, 20, 40 μM (post-OGD/R incubation); 10 μM (optimal, 24 h incubation)
Incubation Time:

24 h (optimal concentration incubation); 2 h (CCK-8 solution incubation)
Result:

Increased NSC viability significantly at all tested concentrations, with 10 μM showing the most potent effect on proliferation.
Reached the highest proliferation rate 24 h post-treatment.

Cell Proliferation Assay^[2]

Cell Line:

cultured adult subventricular zone (SVZ)-derived neural stem cells (NSCs) under oxygen-glucose deprivation/reoxygenation (OGD/R) conditions
Concentration:

10 μM (post-OGD/R incubation); 50 μM (EdU medium)
Incubation Time:

24 h (post-OGD/R incubation); 2 h (EdU medium incubation)
Result:

Increased the number of EdU-positive cells significantly compared to the OGD/R-only group, with approximately 30% of control cells being EdU-positive and OGD/R treatment already increasing proliferative capacity.

Western Blot Analysis^[2]

Cell Line:

Mouse neural stem cells (NSCs)
Concentration:

10 μM
Incubation Time:

24 h
Result:

Upregulated the expression of p-Akt, p-CREB, DCX, and NeuN.

体内実験

2'-Acetylacteoside (2'-AA) (10-40 mg/kg/day; p.o.; daily; 12 weeks) exhibits significant anti-osteoporotic activity in ovariectomized mice, all doses improving trabecular bone microarchitecture and biomechanical strength via inhibition of the RANKL/RANK/TRAF6-mediated NF-κB/NFATc1 pathway^[1].
2'-Acetylacteoside (2'-AA) (total glycosides of Cistanche deserticola, p.o.) was detected in brain tissue, and specifically binds to the central target MAO‑B in the brain as determined by UPLC-Q-Exactive-Orbitrap MS^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming (female, 8-week-old, 26 g, osteoporosis induced by bilateral ovariectomy)^[1]
Dosage:

10 mg/kg/day; 20 mg/kg/day; 40 mg/kg/day
Administration:

p.o.; daily; 12 weeks
Result:

Left body, uterus, and vagina weights unchanged in OVX mice.Enhanced femoral mechanical properties, trabecular BMD, BMC, TMC, BVF, Tb.Th, and Tb.N.Reduced trabecular separation across all doses.
Inhibited serum TRAP, cathepsin K, and DPD activities at 40 mg/kg/day.
Diminished bone resorption markers significantly at lower doses.
Showed no significant effect on bone formation markers (ALP, BGP).
Downregulated RANK, TRAF6, IKKβ, NF‑κB, and NFATc1 expression, blocking the RANKL/RANK/TRAF6‑mediated NF‑κB/NFATc1 pathway.

化学情報

CAS 番号 94492-24-7
性状 Solid
分子量 666.62
分子式 C₃₁H₃₈O₁₆
Color Off-white to light yellow
SMILES

OC1=CC=C(/C=C/C(O[C@H]2[C@H](O[C@]3([H])O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](OC(C)=O)[C@H](OCCC4=CC=C(O)C(O)=C4)O[C@@H]2CO)=O)C=C1O
別名

2'-AA; 2'-アセチルアクテオシド
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Neurotox Res

Tubuloside B Alleviates Aβ25-35 Induced PC12 Cell Injury by Attenuating Pyroptosis, Apoptosis and Excessive Autophagy. [Abstract]

2026 Mar 19;44(2):12. PMID: 41854817

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (150.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : ≥ 100 mg/mL (150.01 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5001 mL

7.5005 mL

15.0010 mL

5 mM

0.3000 mL

1.5001 mL

3.0002 mL

10 mM

0.1500 mL

0.7501 mL

1.5001 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline